Phase II Study of PXD 101 (NSC 726630) as Second-Line Therapy for Treatment of Patients With Malignant Pleural Mesothelioma.
Phase of Trial: Phase II
Latest Information Update: 20 Apr 2018
At a glance
- Drugs Belinostat (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- 05 Mar 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 28 Nov 2007 Status changed from suspended to in progress.
- 26 Jun 2006 New trial record.